Global Macular Degeneration (AMD) and Other Retinal Diseases Market Research Report 2022
1 Report Overview
- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
2 Global Growth Trends
- 2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Perspective (2017-2028)
- 2.2 Macular Degeneration (AMD) and Other Retinal Diseases Growth Trends by Region
- 2.2.1 Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region: 2017 VS 2021 VS 2028
3 Competition Landscape by Key Players
- 3.1 Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Revenue
- 3.1.1 Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Revenue (2017-2022)
4 Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Type
- 4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Type (2017-2022)
- 4.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Type (2023-2028)
5 Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Application
- 5.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Application (2017-2022)
- 5.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Application (2023-2028)
6 North America
- 6.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2017-2028)
- 6.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022)
- 6.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028)
- 6.4 United States
- 6.5 Canada
7 Europe
- 7.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2017-2028)
- 7.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022)
- 7.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028)
- 7.4 Germany
- 7.5 France
- 7.6 U.K.
- 7.7 Italy
- 7.8 Russia
- 7.9 Nordic Countries
8 Asia-Pacific
- 8.1 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2017-2028)
- 8.2 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022)
- 8.3 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028)
- 8.4 China
- 8.5 Japan
- 8.6 South Korea
- 8.7 Southeast Asia
- 8.8 India
- 8.9 Australia
9 Latin America
- 9.1 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2017-2028)
- 9.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022)
- 9.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028)
- 9.4 Mexico
- 9.5 Brazil
10 Middle East & Africa
- 10.1 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2017-2028)
- 10.2 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022)
- 10.3 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028)
- 10.4 Turkey
- 10.5 Saudi Arabia
- 10.6 UAE
11 Key Players Profiles
- 11.1 Regeneron Pharmaceuticals
- 11.1.1 Regeneron Pharmaceuticals Company Detail
12 Analyst's Viewpoints/Conclusions
13 Appendix
- 13.1 Research Methodology
- 13.1.1 Methodology/Research Approach
Macular degeneration (AMD) and other retinal diseases are mainly related to long-term and chronic light damage in macular area, choroidal vascular sclerosis, and aging of retinal pigment epithelial cells, often including Lucentis, Eylea, Avastin and other brands.
Industry Insights
The global Macular Degeneration (AMD) and Other Retinal Diseases market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Macular Degeneration accounting for % of the Macular Degeneration (AMD) and Other Retinal Diseases global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Macular Degeneration (AMD) and Other Retinal Diseases market size is valued at US$ million in 2021, while the North America and Europe Macular Degeneration (AMD) and Other Retinal Diseases are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Macular Degeneration (AMD) and Other Retinal Diseases landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Macular Degeneration (AMD) and Other Retinal Diseases market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Macular Degeneration (AMD) and Other Retinal Diseases market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Macular Degeneration (AMD) and Other Retinal Diseases market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Macular Degeneration (AMD) and Other Retinal Diseases market.
Impact of Covid-19 Outbreak
This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.
Segmental Analysis
The report has been segmented into product and application segments. The researchers have documented all the products present today in the Macular Degeneration (AMD) and Other Retinal Diseases market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.
Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Type
Macular Degeneration
Diabetic Macular Edema
Diabetic Retinopathy(DR)
Retinal Vein Occlusion
Wet Age-Related Macular Degeneration (wAMD)
Dry Age-Related Macular Degeneration (dAMD)
Other
Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Application
Hospital
Clinic
Other
Regional Analysis
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Competitive Landscape
This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:
Regeneron Pharmaceuticals
Bayer HealthCare
Novartis
Roche
Kanghong Pharma
Merck
Allergan
Santen Pharmaceutical
GlaxoSmithKline Pharmaceuticals
Pfizer
Acucela
Valent Pharmaceuticals
IVERIC
Frequently Asked Questions
What factors will challenge the Macular Degeneration (AMD) and Other Retinal Diseases market growth?
Which end-use segment will expand at the fastest CAGR in the Macular Degeneration (AMD) and Other Retinal Diseases market?
Which are the emerging players in the Macular Degeneration (AMD) and Other Retinal Diseases market?
How concentrated is the Macular Degeneration (AMD) and Other Retinal Diseases market?
Which factors are positively contributing to the Macular Degeneration (AMD) and Other Retinal Diseases market growth?
Which are the novel product innovations in the Macular Degeneration (AMD) and Other Retinal Diseases market?
Which product segment will emerge as the most lucrative in the Macular Degeneration (AMD) and Other Retinal Diseases market?
Which factors are increasing the competition in the Macular Degeneration (AMD) and Other Retinal Diseases market?
Which are the strategic measures taken by the Macular Degeneration (AMD) and Other Retinal Diseases industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the Macular Degeneration (AMD) and Other Retinal Diseases market in the coming years?